The New England journal of medicine, 2018-01, Vol.378 (4), p.331-344
- Connors, Joseph M
- Jurczak, Wojciech
- Straus, David J
- Ansell, Stephen M
- Kim, Won S
- Gallamini, Andrea
- Younes, Anas
- Alekseev, Sergey
- Illés, Árpád
- Picardi, Marco
- Lech-Maranda, Ewa
- Oki, Yasuhiro
- Feldman, Tatyana
- Smolewski, Piotr
- Savage, Kerry J
- Bartlett, Nancy L
- Walewski, Jan
- Chen, Robert
- Ramchandren, Radhakrishnan
- Zinzani, Pier L
- Cunningham, David
- Rosta, Andras
- Josephson, Neil C
- Song, Eric
- Sachs, Jessica
- Liu, Rachael
- Jolin, Hina A
- Huebner, Dirk
- Radford, John
2018
Details
- Autor(en) / Beteiligte
- Connors, Joseph M
- Jurczak, Wojciech
- Straus, David J
- Ansell, Stephen M
- Kim, Won S
- Gallamini, Andrea
- Younes, Anas
- Alekseev, Sergey
- Illés, Árpád
- Picardi, Marco
- Lech-Maranda, Ewa
- Oki, Yasuhiro
- Feldman, Tatyana
- Smolewski, Piotr
- Savage, Kerry J
- Bartlett, Nancy L
- Walewski, Jan
- Chen, Robert
- Ramchandren, Radhakrishnan
- Zinzani, Pier L
- Cunningham, David
- Rosta, Andras
- Josephson, Neil C
- Song, Eric
- Sachs, Jessica
- Liu, Rachael
- Jolin, Hina A
- Huebner, Dirk
- Radford, John
- Titel
- Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
- Ist Teil von
- The New England journal of medicine, 2018-01, Vol.378 (4), p.331-344
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2018
- Link zum Volltext
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- In a large randomized trial that compares regimens in which brentuximab vedotin replaced bleomycin, the group receiving the brentuximab had a 4.9 percentage-point improvement in modified progression-free survival, less pulmonary toxicity, and more myelotoxicity and neurotoxicity.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1708984Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5819601
- Format
- –
- Schlagworte
- Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Bleomycin, Bleomycin - administration & dosage, Brentuximab Vedotin, Cancer therapies, CD30 antigen, Chemotherapy, Clinical trials, Colony-stimulating factor, Dacarbazine, Dacarbazine - administration & dosage, Death, Disease-Free Survival, Doxorubicin, Doxorubicin - administration & dosage, Drug dosages, Female, Follow-Up Studies, Granulocyte colony-stimulating factor, Hematology, Hodgkin Disease - drug therapy, Hodgkin Disease - mortality, Hodgkin's lymphoma, Humans, Immunoconjugates - administration & dosage, Immunoconjugates - adverse effects, Immunologic Factors - administration & dosage, Immunologic Factors - adverse effects, Immunotherapy, Leukocytes (granulocytic), Lymphoma, Male, Medicine, Middle Aged, Monoclonal antibodies, Neoplasm Staging, Neutropenia, Neutropenia - chemically induced, Oncology, Peripheral neuropathy, Prophylaxis, Survival, Survival Rate, Targeted cancer therapy, Toxicity, Vinblastine, Vinblastine - administration & dosage, Young Adult